NCT02044354 2026-04-01
CABA-DOC
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed
Clinical Trials
14 trialsNCT05457257 2025-12-19
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
AstraZeneca
Phase 4 Completed
NCT02141438 2025-10-16
REASSURE
Bayer
Completed
NCT04158245 2025-09-22
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
Tulane University
Phase 2 Completed
NCT05544227 2025-07-23
Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer
Williams Cancer Foundation
Phase 1 Completed
NCT04060394 2024-10-10
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
Laekna Limited
Phase 1/2 Completed
NCT03835533 2024-04-12
PORTER
Parker Institute for Cancer Immunotherapy
Phase 1 Completed
NCT05252364 2024-03-21
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer
Hinova Pharmaceuticals Inc.
Phase 1 Completed
NCT02987543 2023-10-06
Study of Olaparib (Lynparzaâ„¢) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
AstraZeneca
Phase 3 Completed
NCT05725070 2023-10-06
Phase 0/1 Study of 212Pb-NG001 in mCRPC
ARTBIO Inc.
Phase EARLY_PHASE1 Completed
NCT04000776 2023-08-28
3TMPO (Triple-Tracer Strategy Against Metastatic Prostate Cancer
Université de Sherbrooke
Completed
NCT04676607 2023-06-13
SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Completed
NCT01942837 2022-10-24
Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04268628 2022-01-03
EXPLORE
Janssen-Cilag Farmaceutica Ltda.
Completed